Rationale and Study Design of the PARERE Trial: Randomized phase II Study of Panitumumab Re-Treatment Followed by Regorafenib Versus the Reverse Sequence in RAS and BRAF Wild-Type Chemo-Refractory Metastatic Colorectal Cancer Patients
Roberto Moretto, Daniele Rossini, Iolanda Capone, Alessandra Boccaccino, Federica Perrone, Elena Tamborini, Gianluca Masi, Carlotta Antoniotti, Federica Marmorino, Veronica Conca, Beatrice Borelli, Angelo Martignetti, Irene Pecora, Francesca Simionato, Samanta Cupini, Margherita Ambrosini, Paolo Manca, Filippo Pietrantonio, Alfredo Falcone, Chiara Cremolini
Topics & Concepts
PanitumumabRegorafenibMedicineCetuximabInternal medicineOncologyIrinotecanColorectal cancerClinical endpointRefractory (planetary science)Progression-free survivalKRASPhases of clinical researchBevacizumabRandomized controlled trialClinical trialChemotherapyCancerAstrobiologyPhysicsColorectal Cancer Treatments and StudiesCancer Genomics and DiagnosticsLung Cancer Treatments and Mutations